Covered recipient · General Payments record
STACY Y KASITINON
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2024
$1,671.19
- Reported across 17 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,653.19 | 16 |
| Travel and Lodging | $18.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $726.63 | 9 |
| Amgen Inc. | $145.46 | 1 |
| GENZYME CORPORATION | $123.45 | 1 |
| E.R. Squibb & Sons, L.L.C. | $121.91 | 1 |
| UCB, Inc. | $118.45 | 1 |
| Arcutis Biotherapeutics, Inc. | $117.76 | 1 |
| Lilly USA, LLC | $116.15 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $104.07 | 1 |
| Galderma Laboratories, L.P. | $97.31 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $1,671.19 | 17 |
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $30.03 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036287 | CMS |
| ABBVIE INC. | $68.00 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036289 | CMS |
| ABBVIE INC. | $30.03 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036291 | CMS |
| ABBVIE INC. | $18.00 | 03/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104190840 | CMS |
| ABBVIE INC. | $97.42 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036293 | CMS |
| ABBVIE INC. | $129.53 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036295 | CMS |
| ABBVIE INC. | $124.69 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036297 | CMS |
| ABBVIE INC. | $124.68 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036299 | CMS |
| ABBVIE INC. | $104.25 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104036301 | CMS |
| Amgen Inc. | $145.46 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117594261 | CMS |
| Arcutis Biotherapeutics, Inc. | $117.76 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1121074201 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $104.07 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118019122 | CMS |
| E.R. Squibb & Sons, L.L.C. | $121.91 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101322472 | CMS |
| Galderma Laboratories, L.P. | $97.31 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145307969 | CMS |
| GENZYME CORPORATION | $123.45 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139966489 | CMS |
| Lilly USA, LLC | $116.15 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135429505 | CMS |
| UCB, Inc. | $118.45 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143265067 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.